[go: up one dir, main page]

AU2002243314A1 - Immunogenic cancer peptides and uses thereof - Google Patents

Immunogenic cancer peptides and uses thereof

Info

Publication number
AU2002243314A1
AU2002243314A1 AU2002243314A AU4331402A AU2002243314A1 AU 2002243314 A1 AU2002243314 A1 AU 2002243314A1 AU 2002243314 A AU2002243314 A AU 2002243314A AU 4331402 A AU4331402 A AU 4331402A AU 2002243314 A1 AU2002243314 A1 AU 2002243314A1
Authority
AU
Australia
Prior art keywords
cancer peptides
immunogenic cancer
immunogenic
peptides
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002243314A
Inventor
Emanuel Calenoff
Charles C. Ditlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of AU2002243314A1 publication Critical patent/AU2002243314A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002243314A 2000-11-27 2001-11-13 Immunogenic cancer peptides and uses thereof Abandoned AU2002243314A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/723,307 2000-11-27
US09/723,307 US6892140B1 (en) 2000-11-27 2000-11-27 Immunogenic cancer peptides and uses thereof
PCT/US2001/047734 WO2002047613A2 (en) 2000-11-27 2001-11-13 Immunogenic cancer peptides and uses thereof

Publications (1)

Publication Number Publication Date
AU2002243314A1 true AU2002243314A1 (en) 2002-06-24

Family

ID=24905675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243314A Abandoned AU2002243314A1 (en) 2000-11-27 2001-11-13 Immunogenic cancer peptides and uses thereof

Country Status (3)

Country Link
US (2) US6892140B1 (en)
AU (1) AU2002243314A1 (en)
WO (1) WO2002047613A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961969A (en) 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
US7041506B2 (en) * 2001-11-19 2006-05-09 Becton Dickinson And Company Peptides promoting cell adherence, growth and secretion
US8263746B2 (en) * 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
RU2425841C2 (en) 2005-10-12 2011-08-10 МорфоСис АГ Preparation and analysis of completely human medical antibodies - human cd38 specific hucal gold derivatives
EP2445529A4 (en) * 2009-05-21 2012-11-28 Univ Central Florida Res Found IN CANCER STEM CELLS DIFFERENTLY EXPRESSED MARKERS AND METHOD OF USE THEREOF
US20130309234A1 (en) * 2012-05-18 2013-11-21 Trion Pharma Gmbh Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome
US9315567B2 (en) * 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9382329B2 (en) * 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US10898563B2 (en) * 2016-02-29 2021-01-26 The Curators Of The University Of Missouri Cancer immune-based therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4585742A (en) 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof
US5194254A (en) 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
WO1991004040A1 (en) 1989-09-15 1991-04-04 Biomeasure, Inc. Treatment of colon cancer
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
KR100278157B1 (en) 1992-06-25 2001-01-15 장 스테판느 Vaccine Compositions Containing Supplements
JP2745363B2 (en) * 1992-09-25 1998-04-28 富士写真フイルム株式会社 Silver halide photographic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
AU6102494A (en) * 1993-02-05 1994-08-29 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US5763164A (en) 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US5738852A (en) 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
US5620955A (en) 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
RU2041261C1 (en) 1993-08-11 1995-08-09 Институт молекулярной биологии им.В.А.Энгельгардта РАН Method for manufacturing of matrix for detecting of mismatches
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
CN1149887A (en) 1994-04-22 1997-05-14 科里克萨有限公司 Compounds and methods for stimulation and enhancement of protective immune responses and IL-12 production
AU686840B2 (en) 1994-07-07 1998-02-12 Immunex Corporation Fusion proteins comprising GM-CSF and antigens and their expression in yeast
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
CA2210160A1 (en) 1995-01-18 1996-07-25 Roger Jeffcoat Cosmetics containing thermally-inhibited starches
US6106829A (en) 1995-01-20 2000-08-22 Human Genome Sciences, Inc. Human prostatic specific reductase
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5861247A (en) 1996-01-26 1999-01-19 University Of Chicago Rapid method to detect duplex formation in sequencing by hybridization methods
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
IN183280B (en) 1996-09-20 1999-10-30 Univ New Mexico
US6261791B1 (en) * 1997-03-10 2001-07-17 The Regents Of The University Of California Method for diagnosing cancer using specific PSCA antibodies
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US5982270A (en) * 1998-12-03 1999-11-09 Shop Vac Corporation Thermal fuse
US6376654B1 (en) * 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof

Also Published As

Publication number Publication date
US20050048588A1 (en) 2005-03-03
WO2002047613A3 (en) 2003-08-21
US6892140B1 (en) 2005-05-10
WO2002047613A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001295540A1 (en) Arylsulfatase-inhibitors in deodorants and antiperspirants
AU2002211717A1 (en) Stresscopins and their uses
AU2001290860A1 (en) Spas-1 cancer antigen
AUPQ342599A0 (en) Conjugates and uses thereof
AU2002243392A1 (en) Immunogenic proteoliposomes, and uses thereof
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU2001229439A1 (en) Bioconjugates and uses thereof
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2001252917A1 (en) 7 human ovarian and ovarian cancer associated proteins
AU2001242342A1 (en) Antiperspirants
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2001288102A1 (en) Solid preparations
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2001282521A1 (en) OCT preparations
AU2001272427A1 (en) Solid preparations
AU5979300A (en) Angiopoietin-6 and uses thereof
AU5632500A (en) Cancer associated antigens and uses therefor
AU4553100A (en) Tumour-associated antigen
AU2001231141A1 (en) Novel human septin and uses thereof
AU2001277519A1 (en) Bio-probes and use thereof